6533b825fe1ef96bd1283468

RESEARCH PRODUCT

Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?

Vincenza CalvarusoAntonio Craxì

subject

Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularGuanineLiver fibrosisOrganophosphonatesAdministration Oralmedicine.disease_causeGastroenterologyAntiviral AgentsFibrosisInternal medicinemedicineHumansIn patientTenofovirHepatitis B virusTelbivudineHepatologybusiness.industryAdeninecirrhosisLiver NeoplasmsAntiviral therapyNucleosidesmedicine.diseaseHepatitis BFibrosisdigestive system diseasesLamivudineHepatocellular carcinomaLiver functionbusinessThymidine

description

Long-lasting HBV-DNA suppression is considered to be the best surrogate end-point of antiviral therapy in patients with hepatitis B virus (HBV) related chronic hepatitis or cirrhosis, and it is a prerequisite to prevent liver-related complications and improve survival. Treatment with oral antiviral drugs in patients with HBV cirrhosis is effective in restoring liver function and improving survival even in those with decompensated cirrhosis. These agents are generally well-tolerated for long-term treatment, and several evidences have demonstrated that they are able to reverse liver fibrosis and prevent the occurrence of HCC.

yearjournalcountryeditionlanguage
2014-02-01
10.1111/liv.12395http://hdl.handle.net/10447/88284